@article {Wendt2020.11.23.20235846, author = {Frank R Wendt and Dora Koller and Gita A Pathak and Daniel Jacoby and Edward J Miller and Renato Polimanti}, title = {Biobank scale pharmacogenomics informs the genetic underpinnings of simvastatin use}, elocation-id = {2020.11.23.20235846}, year = {2020}, doi = {10.1101/2020.11.23.20235846}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background and Purpose Studying drug metabolizing enzymes, encoded by pharmacogenes (PGx), may inform biological mechanisms underlying the diseases for which a medication is prescribed. Until recently, PGx loci could not be studied at biobank scale. Here we analyze PGx haplotype variation to detect associations with medication use in the UK Biobank.Methods In 7,649 unrelated African-ancestry (AFR) and 326,214 unrelated European-ancestry (EUR) participants from the UK Biobank, aged 37-73 at time of recruitment, we associated clinically-relevant PGx haplotypes with 265 (EUR) and 17 (AFR) medication use phenotypes using generalized linear models covaried with sex, age, age2, sex{\texttimes}age, sex{\texttimes}age2, and ten principal components of ancestry. Haplotypes across 50 genes were assigned with Stargazer. Our analyses focused on the association of PGx haplotype dose (quantitative predictor), diplotype (categorical predictor), and rare haplotype burden on medication use.Results In EUR, NAT2 metabolizer phenotype (OR=1.05, 95\% CI: 1.03-1.08, p=7.03{\texttimes}10-6) and activity score (OR=1.09, 95\% CI: 1.05-1.14, p=2.46{\texttimes}10-6) were associated with simvastatin use. The dose of N-acetyltransferase 2 (NAT2)*1 was associated with simvastatin use relative to NAT2*5 (NAT2*1 OR=1.04, 95\% CI=1.03-1.07, p=1.37{\texttimes}10-5) and was robust to effects of low-density lipoprotein cholesterol (LDL-C) concentration (NAT2*1 given LDL-C concentration: OR=1.07, 95\% CI=1.05-1.09, p=1.14{\texttimes}10-8) and polygenic risk for LDL-C concentration (NAT2*1 given LDL-C PRS: OR=1.09, 95\% CI=1.04-1.14, p=2.26{\texttimes}10-4). Interactive effects between NAT2*1, simvastatin use, and LDL-C concentration (OR: 0.957, 95\% CI=0.916-0.998, p=0.045) were replicated in eMERGE PGx cohort (OR: 0.987, 95\% CI: 0.976-0.998, p=0.029).Conclusions and relevance We used biobank-scale data to uncover and replicate a novel association between NAT2 locus variation (and suggestive evidence with several other genes) and better response to simvastatin (and other statins) therapy. The presence of NAT2*1 versus NAT2*5 may therefore be useful for making clinically informative decisions regarding the potential benefit (e.g., absolute risk reduction) in LDL-C concentration prior to statin treatment.Subject terms genetics, genetic association studies, cardiovascular diseaseCompeting Interest StatementEJM reports grants from Bracco and Eidos, consulting for General Electric, Alnylam, and Pfizer. DJ has served as consultant and steering committee member for MyoKardia, Inc.Funding StatementThis study was supported by the National Institutes of Health (R21 DC018098 (RP), R21 DA047527 (RP), and F32 MH122058 (FRW)).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was exempt from Yale IRB review due to use of deidentified data. UKB data were accessed via reference number 58146 and are available to other bona fide researchers though the UKB Data Access Management System. UK Biobank has obtained Research Tissue Bank (RTB) approval from its ethics committee. Pilot sequencing data from eMERGE PGx were accessed through dbGAP (dbGaP Study Accession: phs000906.v1.p1) and are available to bone fide researchers through dbGAP Authorized Access application. Cohort-level consent was collected for participants following ethics procedures at each contributing site.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in this manuscript are provided as supplementary information. Individual level data may be accessed by bone fide researchers through the UK Biobank. This research has been conducted using the UK Biobank Resource (application reference no. 58146). https://www.ukbiobank.ac.uk/data-showcase/ https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000906.v1.p1 AFRAfrican ancestryASactivity scoreEUREuropean ancestryGWASgenome-wide association studyLDL-Clow-density lipoprotein cholesterolMPmetabolizer phenotypePGxPharmacogenePRSpolygenic risk scoreUKBUnited Kingdom BiobankVCFvariant call format (file type)VIPvery important pharmacogene}, URL = {https://www.medrxiv.org/content/early/2020/11/24/2020.11.23.20235846}, eprint = {https://www.medrxiv.org/content/early/2020/11/24/2020.11.23.20235846.full.pdf}, journal = {medRxiv} }